Association between the B-RAF/N-RAS mutations, the CDKN2A alterations and the MC1R variants in melanoma

treat, owing to its ability to spread quickly and its relative resistance to chemotherapeutic intervention. Unfortunately, current treatments for melanoma do not provide much relief, with few contributing to the overall survival of patients with advanced metastatic disease. The lack of accurate prognostic indicators and effective therapies emphasizes the need for a better understanding of genetic and phenotypic changes in melanoma formation and progression.